HAVCR2 and cancer: To further augment the anti-cancer efficacy of CAR-T cells, it is essential to evaluate T cell activity by biomarkers including PD-1, LAG-3 and TIM-3, which contributes to facilitate the identification of high-quality T cells for clinical application.